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Abstract
The physiologically predominant signal for pancreatic beta cells to secrete insulin is glucose. 
While circulating glucose levels and beta cell glucose metabolism regulate the amount of released 
insulin, additional signals emanating from other tissues and from neighbouring islet endocrine 
cells modulate beta cell function. To this end, each individual beta cell can be viewed as a sensor 
of a multitude of stimuli that are integrated to determine the extent of glucose-dependent insulin 
release. This review discusses recent advances in our understanding of inter-organ 
communications that regulate beta cell insulin release in response to elevated glucose levels.
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Intestine to beta cell communication
Incretin hormones
The incretin hormones glucagon-like peptide 1 (GLP-1) (1–4) and glucose-dependent 
insulinotropic polypeptide (GIP, also known as gastric inhibitory polypeptide) are among 
the most widely studied modulators of beta cell function (5–8).
GLP-1—GLP-1, a proteolytic product of pre-proglucagon, which is synthesised and 
secreted from intestinal L cells upon stimulation by intestinal nutrients, is released into the 
circulation shortly after meal intake, increasing circulating GLP-1 levels. At the endocrine 
pancreas, through binding to its cognate stimulatory G protein (Gαs)-coupled receptor 
(GLP-1R), it suppresses alpha cell glucagon secretion and potentiates insulin secretion from 
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beta cells in a glucose-dependent manner. It is important to note that GLP-1 action on beta 
cells only occurs when the circulating glucose level is above a certain threshold, which in 
humans lies in the low normoglycaemic range. In the presence of elevated glucose levels, 
beta cell GLP-1R stimulation results in a more pronounced rise in intracellular calcium, and 
the frequency and number of insulin vesicles exocytosed (i.e. insulin secretion) is increased. 
GLP-1 is rapidly degraded enzymatically by dipeptidyl peptidase IV (DPP-IV) located in the 
endothelium, rendering the biological half-life of GLP-1 shorter than 5 min (9)
The above-described concept of GLP-1–GLP-1R action is successfully exploited by diabetes 
pharmacotherapy, with GLP-1R agonists or DPP-IV inhibitors that both augment GLP-1 
action in beta cells and increase insulin secretion in patients with type 2 diabetes mellitus. In 
general, in type 2 diabetic patients, the meal-induced increase in circulating GLP-1 levels is 
similar to that observed in non-diabetic individuals; however, it is not as effective in 
potentiating insulin secretion. The underlying reasons for this remain incompletely 
understood (9). Experimental findings suggest that signals external to beta cells inhibit the 
beta cell response to incretin action (see below) and that, at least in humans with a prolonged 
history of type 2 diabetes, a beta cell autonomous defective response to GLP-1 is 
demonstrable during experimental studies on isolated islets, attributable to the loss of key 
beta cell-defining transcription factors (10).
Recent studies using sophisticated genetic mouse models have provided new insights into 
the physiological and pharmacological mechanisms of GLP-1 action. Mouse models of 
conditional, tissue-specific GLP-1R ablation (11) indicate that the presence of GLP-1R on 
beta cells is not necessary for physiological (not during diabetes and insulin resistance) 
GLP-1 action in modulating beta cell function, and suggest the possibility that GLP-1R 
activation in afferent neurons located in the intestine or portal venous vasculature may relay 
GLP-1 action indirectly via neuronal mechanisms to beta cells (11). Selective beta cell 
ablation of GLP-1R in mice did not alter insulin secretion or glucose tolerance during oral or 
intraperitoneal glucose tolerance tests, while systemic treatment of these mice with a 
pharmacological GLP-1R agonist did result in the absence of insulin secretion potentiation. 
The investigators of these studies concluded that, under physiological conditions, incretin 
action through GLP-1R is independent of the presence of GLP-1R on beta cells, and that the 
effects of GLP-1 may be mediated via non-endocrine mechanisms. These findings raise the 
possibility that in type 2 diabetes the absence of incretin action may not be solely due to the 
diminished response of beta cells to GLP-1, but, rather, may be due to disruptions in 
neuronal relay mechanisms between the intestine and the endocrine pancreas (11).
In addition to GLP-1, L cells synthesise and secrete other endocrine hormones that may 
influence beta cell function. In the rat, the epithelium of the proximal portion of the intestine 
contains L cells that produce cholecystokinin (CCK) and neurotensin, while distally 
localised L cells express peptide YY (PYY) (12).
GIP and xenin-25—In contrast to GLP-1 agonist treatment, pharmacological 
administration of GIP fails to augment glucose-stimulated insulin secretion (GSIS) in 
humans with type 2 diabetes. The mechanisms of action of GIP, which is secreted from 
intestinal epithelial K cells, as an incretin hormone appear to be more complex than those of 
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GLP-1. Importantly, a second protein, called xenin-25, is co-synthesised and secreted from 
K cells (13). Mice selectively lacking K cells exhibit a blunted response to exogenous GIP 
replacement, and in vivo co-administration of xenin-25 restores GIP incretin action (13). In 
vitro studies on xenin-25 and GIP treatment of mouse islets indicate that xenin-25 does not 
act directly on beta cells. Rather, xenin-25 acts by stimulating cholinergic signalling to beta 
cells via non-ganglionic circuitry that, to date, remains to be characterised (14).
Co-administration of xenin-25 with GIP potentiates GSIS in non-diabetic people but not in 
individuals with established type 2 diabetes. However, co-treatment with recombinant 
xenin-25 and GIP reduces postprandial glycemia by delaying gastric emptying in humans 
with or without type 2 diabetes (15). Thus, while GIP is considered an incretin hormone, its 
mechanisms of action and its significance in glucoregulation remain to be fully understood. 
Importantly, establishing why combined recombinant xenin-25/GIP treatment is ineffective 
in type 2 diabetic patients may further our understanding of beta cell failure in type 2 
diabetes.
Furthermore, studies in mice lacking GIP (as opposed to lacking K cells, described above) 
suggest a wider role for GIP in metabolic control. Absence of GIP production in mice, 
slightly impairs GSIS and glucose tolerance. However, when placed on a high-fat content 
diet, the absence of GIP protects against obesity and insulin resistance and maintains 
increased fatty acid oxidation (16).
More recently, studies of GIP receptor (GIPR) ablation specifically in mouse beta cells (17) 
reveal at least two signalling pathways that are engaged by GIPR activation in beta cells. 
The first is the well-known activation of cyclic AMP (cAMP) production, the second is the 
extracellular signal-regulated kinase (ERK)-dependent pathway. GIPR–ERK but not cAMP-
dependent signalling in beta cells stimulates the expression of T cell-specific transcription 
factor-1 (TCF1), which is encoded by Tcf7 (17). Mice lacking GIPR specifically in beta 
cells exhibit normal glucose tolerance, while glucose-stimulated insulin secretion is slightly 
dampened. Interestingly, the response to GLP-1R activation in GIPR-ablated islets is 
augmented, suggesting potential compensatory mechanisms that maintain insulin secretion 
in the absence of GIPR signalling.
Importantly, Tcf7 levels are lower in islets of diabetic mice and in humans with type 2 
diabetes, and Tcf7−/− mice exhibit increased susceptibility to apoptotic injury and glucose 
intolerance with aging or during increased metabolic demand in the fact of high fat content 
diet feeding (17) The antiapoptotic actions in beta cells of TCF1 are likely to be mediated by 
the TCF7 target pituitary tumour-transforming gene 1 (Pttg1), which encodes securin, a 
protein involved in DNA repair and chromosome stabilising mechanisms. Thus, a GLP-1R-
independent, GIPR–ERK–TCF1–PTTG1 axis is proposed to exert protective and 
antiapoptotic effects on beta cells (17).
Decretin hormones
Neuromedin U—While the incretin hormones stimulate increased insulin release from 
beta cells in the feeding state, prolonged nutrient deprivation and fasting are accompanied 
by reduced insulin secretion (i.e. ‘fasting diabetes’) (18). This dampened insulin secretion is 
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not readily reversed by i.v. glucose supply, arguing against a simple absence of nutrients 
(i.e. glucose) and for an active suppression of beta cell insulin secretion as a regulatory 
mechanism of beta cell function during periods of nutrient deprivation (17). Such 
observations have propagated the concept of decretin hormones that act during fasting to 
regulate in a manner inverse to that of incretins.
Indeed, using a nutrition-deprived Drosophila melanogaster model, limostatin was found to 
be upregulated in gut-associated endocrine cells and to suppress secretion from Drosophila 
insulin-like peptide-producing cells by interacting with the Drosophila orthologue of the 
inhibitory neuromedin U receptor (NMUR) (19). NMUR1 is a G protein-coupled receptor 
that, in mammals, mediates the peripheral actions of NMU. It can be localised to human beta 
cells, and in perifusion assays of human islets, NMU suppresses GSIS. Furthermore, in 
humans, NMU expression is detectable in foregut-derived stomach and duodenum, and its 
immunoreactivity is localised to chromogranin B-positive enteroendocrine cells in the 
duodenal epithelium (19). Circulating NMU concentrations during fasting and feeding have 
not been reported to date. Although it is unclear whether NMU fulfils this classical criterion 
of a bone fide hormone, NMU appears to possess all the other properties expected of a 
decretin (19).
Remarkably, an NMU variant, NMU R165W, which in humans confers autosomal-dominant 
early-onset obesity, fails to suppress GSIS in perifusion studies, suggesting a sequential 
pathogenic link between increased insulin secretion followed by increased risk of obesity in 
humans (19).
Ghrelin and galanin—Ghrelin and galanin are two more hormones that are synthesised 
and secreted from the gastrointestinal tract and suppress beta cell glucose responsiveness. 
Ghrelin is produced in foregut-derived stomach epithelium and also in endocrine cells 
located in the pancreatic islet (epsilon cells) (20–22). Specific post-translational acylation by 
ghrelin O-acyltransferase (GOAT) is required for ghrelin to bind to and activate its receptor 
(23). Fasting induces ghrelin expression in both stomach epithelium and the central nervous 
system. Circulating acyl-ghrelin levels increase during nutritional deprivation. Furthermore, 
acyl-ghrelin potently inhibits GSIS in vivo in mice and in cultured islets in vitro via 
interaction with the ghrelin receptor. Ghrelin-deficient mice are less protected from fasting-
induced hypoglycaemia (24, 25). Collectively, these findings indicate that ghrelin may 
function as a fasting-induced hormone, exerting, among other effects, homeostatic effects 
that serve to suppress insulin secretion and protect against hypoglycaemia. Furthermore, 
specific pharmacological inhibition of GOAT, an enzyme with the exclusive function of 
activating ghrelin function, results in increased in vivo insulin secretion and improved 
glucose homeostasis in animal models of diet-induced obesity and glucose intolerance (26).
Galanin is expressed in neuronal and intestinal tissue and, in vitro, suppresses GSIS from 
isolated rodent islets. The regulation of galanin secretion and the mechanisms by which it 
regulates insulin secretion in humans remain unknown. In experimental systems, it is likely 
that galanin inhibits insulin secretion via interaction with a G protein-coupled receptor that 
signals through Gα(o2) (27, 28).
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Liver to beta cell communication
Hyperglucagonaemia has long been recognised as a hallmark of type 2 diabetes. 
Furthermore, subsets of individuals who are at risk for developing type 2 diabetes (i.e. first-
degree relatives of patients with type 2 diabetes) also exhibit relative hyperglucagonemia. 
The mechanistic link between hyperglucagonemia and defective insulin secretion in type 2 
diabetes has recently been elucidated using genetic mouse models (29). Glucagon acts on a 
relatively small number of target cells and orchestrates processes that protect against or aid 
recovery from hypoglycaemia. In the liver, glucagon binds to its Gαs-coupled receptor to 
stimulate cyclic AMP (cAMP) synthesis, which in turn binds to the regulatory subunit of 
protein kinase A (PKA) holoenzyme, thereby releasing and activating the catalytic subunit 
of PKA. Subsequent downstream signalling results in glucose mobilisation from glycogen 
stores and transcriptional upregulation and activation of the gluconeogenesis program (29).
As expected, transgenic hepatocyte-specific overexpression of the catalytic subunit of PKA 
in mice results in the upregulation of the transcriptional gluconeogenesis program and in 
hyperglycaemia. However, insulin secretion remains insufficient to adequately control 
glycaemia. Similarly, selective ablation of the gene encoding PKA regulatory subunit 1a 
(Prkar1a) in hepatocytes also results in increased hepatic glucose production and insulin 
secretion insufficient to control blood glucose levels (29). Mice from the latter study 
harboured a factor in their circulation that inhibited insulin secretion from mouse islets 
cultured in vitro. Gene expression analysis of livers from mice with ablated Prkar1a 
surprisingly revealed the peptide hormone kisspeptin 1 to be upregulated, which in turn 
resulted in elevated circulating kisspeptin 1 levels (30).
The kisspeptin 1 receptor (Kiss1R) is present in abundance on pancreatic beta cells, and 
acute kisspeptin 1 treatment of mice causes impaired glucose tolerance owing to dampened 
GSIS. Kiss1R is related to the galanin and ghrelin receptors, and similar to galanin and 
ghrelin, kisspeptin 1 binds to its cognate receptor and inhibits cAMP production in beta 
cells, thereby dampening GSIS (30). Moreover, mouse models of diabetes mellitus, such as 
the high-fat content diet-fed mouse or the db/db mouse, exhibit elevated liver kisspeptin 1 
production and impaired glucose tolerance. Kisspeptin 1 knockdown in the liver of these 
animal models ameliorates glucose tolerance and increases GSIS. Importantly, humans with 
diabetes also exhibit increased liver kisspeptin 1 production and circulating kisspeptin 1 
levels. Human islets express Kiss1R, and it is likely that, as in the mouse model, kisspeptin 
1 would impair GSIS from human islets (30).
In summary, a tri-hormonal glucoregulatory endocrine circuit exists between the pancreatic 
islet and the hepatocyte. Glucagon stimulates gluconeogenesis in the liver, which raises 
glucose levels and stimulates kisspeptin 1 production, which in turn suppresses insulin 
secretion.
Adipocyte to beta cell communication
Leptin, a hormone produced by adipocytes, suppresses insulin secretion. Pancreatic beta 
cells express the functional long form of the leptin receptor (ObRb), and isolated islets 
incubated in vitro with leptin exhibit reduced GSIS (31–36). Furthermore, in mice, 
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conditional genetic ablation (using the Cre–LoxP system) of ObRb specifically in pancreatic 
beta cells is accompanied by augmented GSIS in vivo. These studies suggest that leptin acts 
directly on pancreatic beta cells to impair insulin secretion. The findings have recently been 
reexamined in light of observations that the transgene carrying Cre recombinase under the 
control of the rat insulin promoter is also expressed ectopically in areas of the brain where 
the leptin receptor is also expressed. More recent studies using a different mouse model of 
beta cell-specific Cre expression while avoiding neuronal Cre expression, suggest that the in 
vivo effects of leptin may not be mediated via its receptor on beta cells (37). Nevertheless, 
as outlined in the section below on the skeletal system, leptin may regulate beta cell function 
indirectly at least in the mouse by controlling bone mass and osteocalcin production.
Adiponectin is another major adipose tissue-derived hormone. In addition to facilitating beta 
cell proliferation and regeneration in mice after in vivo experimental ablation, it has recently 
been shown to modulate beta cell lipid metabolism, thereby protecting beta cells from 
lipotoxicity and preserving beta cell function (38, 39). Further studies related to adiponectin 
receptors are anticipated to elucidate how adiponectin exerts these effects on beta cells.
Other products secreted by adipocytes, such as resistin and fibroblast growth factor 21 
(FGF21), have been proposed to regulate beta cell function (reviewed in (40)). However, 
there are currently insufficient data on these adipocyte-derived products to allow for any 
clear conclusions as to whether these effects occur via direct action on beta cells or 
indirectly via changes in other metabolically relevant tissues (40)
Skeletal system to beta cell communication
Bone
Bone is increasingly being recognised as an endocrine tissue that participates in regulating 
whole body fuel metabolism and glucoregulation. Teleologically, the role of the skeleton as 
a prerequisite for transitioning from marine to terrestrial existence and locomotion would 
posit adaptive processes for metabolic homeostasis (41).
Osteocalcin—In terms of the skeletal compartment, osteocalcin has in recent years 
emerged as an important regulator of beta cell functional mass, insulin sensitivity and 
peripheral tissue fuel combustion, as well as male fertility (42, 43). Osteocalcin, one of the 
most abundant components of bone extracellular matrix is synthesised and secreted by 
osteoblasts. Osteocalcin undergoes post-translational carboxylation on glutamic residues. 
Formation of undercarboxylated osteocalcin (Glu-OCN) or resorption of bone through 
osteoclasts, yielding Glu-OCN, releases undercarboxlated osteocalcin into the circulation, 
allowing it to reach target tissues and act through the osteocalcin receptor (44). Observations 
from osteocalcin knockout mice indicate that osteocalcin plays a role in regulating beta cell 
mass and function (45, 46). Osteocalcin knockout mice exhibit low beta cell mass and 
impaired glucose tolerance owing in part to impaired GSIS and to insulin resistance in 
peripheral tissue. Moreover, osteocalcin treatment in mice increases beta cell mass and 
insulin secretion, improves glucose homoeostasis and prevents the development of type 2 
diabetes (45). Furthermore, mice lacking the presumptive osteocalcin receptor GPRC6A (a 
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Gαs protein-coupled receptor) specifically on beta cells exhibit impaired beta cell 
proliferation, insulin synthesis and GSIS (47).
Remarkably, osteoblasts, which synthesise osteocalcin, express insulin receptors, and insulin 
stimulates osteocalcin production. Mice with an osteoblast-specific lack of insulin receptors 
show reduced bone density, reduced circulating osteocalcin levels and reduced beta cell 
mass, impaired GSIS and glucose tolerance. Conversely, overexpression of insulin receptors 
in osteoblasts improves glucose tolerance in mice on a diabetogenic high-fat diet (HFD). 
These findings suggest a feed-forward interplay between insulin-producing beta cells and 
osteoblasts, osteoclasts and bone turnover (48, 49).
More recently, delta-like 1 (DLK-1) has been proposed to counteract the effects of insulin 
on osteoblasts, providing a counter-regulatory mechanism to the feed-forward loop between 
osteocalcin and insulin. Osteocalcin stimulates DLK-1 production in beta cells, from where 
DLK-1 is co-secreted with insulin. In turn, DLK-1 inhibits insulin receptor signalling in 
osteoblasts (50).
Leptin and adiponectin—Leptin, originating from adipocytes, which are an osteocalcin 
target, acts via the hypothalamus and the sympathetic nervous system to inhibit bone 
formation (51, 52). This, in turn, results in reduced circulating (undercarboxylated) 
osteocalcin, followed by reduced insulin secretion (as outlined above). While these early 
results on the regulation of bone mass by leptin are very convincing, recent studies suggest 
that leptin action in the brain may increase rather than decrease bone mass (53). 
Adiponectin, another adipose tissue product, also participates in the regulation of bone mass 
and osteocalcin production. Adiponectin has opposing effects on bone mass. It directly 
causes osteoblast apoptosis, but via hypothalamic action reduces sympathetic tone and 
counteracts the effects of leptin on bone mass (54).
While these observations on the complex relationship between bone and fuel homeostasis 
were based on mouse model studies, much work remains to be done to evaluate the broader 
significance of these findings in humans in this exciting field. Osteoprotegerin (OPGN), 
recently shown to regulate beta cell proliferation, will be discussed further below (55).
Skeletal muscle
A signalling pathway from the skeletal muscle to the pancreatic islet has been described in 
rodent models. In mice subjected to exercise in spinning wheels, skeletal muscle produces 
IL-6, which reaches pancreatic alpha cells via the circulation and, via its cognate receptor, 
modulates post-translational processing of pro-glucagon to favour the production of GLP-1 
rather than glucagon. In turn, GLP-1 release from alpha cells potentiates GSIS in 
neighbouring beta cells (56). Thus, muscle exercise is reported to modulate beta cell 
function indirectly via IL-6 originating from skeletal muscle, altering pro-glucagon 
processing in alpha cells, and exposing beta cells to higher GLP-1 concentrations (56).
Based on these observations, it is conceivable that exercise not only alters insulin sensitivity 
but also influences beta cell function and insulin secretion. Whether these mechanisms 
described in rodents also apply to humans is at present unclear, but is important to establish 
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as this may further our understanding of the pathogenesis of metabolic disease associated 
with infrequent exercise and have implications for its treatment. Furthermore, recent in vitro 
studies suggest a role for additional myotube-derived factors (‘myokines’) that influence 
beta cell function. These myokines are differentially expressed in normal vs insulin-resistant 
myotubes and appear to act through mitogen-activated protein 4 kinase 4 signalling (57).
Gonads to beta cell communication
The main gonadal sex steroids testosterone (58, 59)and oestrogen (60) have been reported to 
protect pancreatic beta cells from damaging insults such as glucotoxicity or streptozotocin-
induced oxidative stress. In humans, oestrogen replacement in menopausal women reduces 
the incidence of diabetes mellitus. At the molecular level, oestrogen is shown to directly act 
on beta cells to exert prosurvival effects and increase insulin synthesis via oestrogen 
response element (ERE)-independent extranuclear oestrogen receptors ERα, ERβ and 
through the G protein-coupled oestrogen receptor (60–66).’
In male mice with selective ablation of the androgen receptor in beta cells GSIS is impaired, 
leading to reduced glucose tolerance (67). These mice are also less capable of compensating 
for diet-induced insulin resistance compared with controls, and islets isolated from these 
mice exhibit reduced GSIS in vitro, similar to AR antagonist (flutamide)-treated human 
islets (67). Collectively, these observations suggest that the androgen receptor 
physiologically regulates beta cell function in male mice. More detailed work using genetic 
mouse models will be required to elucidate at a molecular level the role for the androgen 
receptor and male sex steroids on beta cell function and survival.
Placenta to beta cell communication
Metabolism changes during pregnancy to meet the maternal and fetal energy requirements. 
Circulating levels of both prolactin and human placental lactogen are elevated to counteract 
pregnancy-related insulin resistance and to regulate functional beta cell mass.
In mice, the tyrosine hydroxylase genes Tph1 and Tph2, encoding isoforms of the rate-
limiting enzyme for serotonin (5-hydroxytryptamine, 5-HT), are upregulated in beta cells 
during pregnancy. Serotonin synthesis is upregulated in the beta cells of pregnant mice and, 
in an autocrine/paracrine fashion, serotonin binds to cognate Gq/11-coupled 5-HT2B 
receptors to stimulate beta cell proliferation (68). Through binding to the 5-HT3 receptor, 
serotonin also reduces the resting membrane potential of beta cells and the threshold for 
GSIS (55, 69). Both prolactin and placental lactogen, acting through the prolactin receptor, 
stimulate tyrosine hydroxylase, establishing this endocrine regulatory communication 
between the placenta and the beta cell. Activated prolactin receptor signalling in beta cells 
also stimulates the production and release of osteoprotegerin (OPGN), a protein that binds to 
and inhibits the receptor activator of NF-κB (RANK) ligand (RANKL). RANKL inhibits 
beta cell proliferation, and its sequestration by OPGN thus releases the brake on beta cell 
proliferation. This mechanism has been confirmed both in mouse and human islets. Thus, 
this second mechanism engaged by the prolactin receptor during pregnancy serves to 
regulate functional beta cell mass (55). It is important to note that the placenta produces 
large amounts of kisspeptin 1 (70), which would be expected to impair beta cell function and 
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insulin secretion. The interplay between kisspeptin 1 and prolactin signalling on beta cells 
has not been experimentally examined.
In summary, beta cells can be viewed as sensors that constantly receive signals from a 
variety of peripheral tissues. These signals, which could have opposing effects, fluctuate 
according to the metabolic state of the source tissues. Upon reaching beta cells, they are 
integrated and modulate insulin secretion in response to the predominant physiological 
stimulus, namely, glucose. How nutrients and metabolites, such as fatty acids and their 
metabolic derivatives, amino acids and metabolic products originating from other tissues 
and from microbiota, interplay with and participate in inter-organ signalling and in 
regulating beta cell function is beyond the scope of this review and deserves a separate 
dedicated review.
Central nervous system regulation of beta cell function
Pancreatic beta cells are innervated by the autonomic nervous system. Studies in humans 
and in rodents following vagotomy have reported reduced GSIS, suggesting that 
parasympathetic innervation supports beta cell function ([71] and references therein). Other 
studies suggest that vagal innervation may also control beta cell proliferation and mass; and 
the ventromedial hypothalamus may negatively regulate vagus-relayed signalling in beta cell 
proliferation (72–75). Recent reports indicate that, in contrast to rodent islets, human islets 
are innervated primarily by cholinergic neurons, suggesting that sympathetic islet 
innervation may be relevant in rodents but not humans (76). Furthermore, in humans, alpha 
cells may also be an additional source of acetylcholine, which acts on beta cells in a 
paracrine fashion (77).
Several neurotransmitters released from peripheral autonomic nerves have been proposed to 
modulate GSIS, including the principal parasympathetic neurotransmitter acetylcholine (71, 
78, 79). The Gq protein-coupled muscarinic M3 acetylcholine receptor (M3R; but not M1R 
or M2R) subtype is expressed at high density on mouse pancreatic beta cells (80), and beta 
cell-specific M3R knockout results in impaired GSIS in mice (81). Furthermore, beta cell-
specific pharmacological activation of this receptor via a M3R–Gq-signalling-coupled 
designer receptor exclusively activated by designer drug (DREADD) potentiates GSIS, and 
after chronic stimulation also stimulates beta cell proliferation (82). Despite these 
observations and the identification of brain nuclei that regulate metabolic controls, such as 
insulin sensitivity and hepatic glucose production (83) and hunger, satiety and food-intake 
(84), distinct brain regions/nuclei, which regulate betacell function through vagal 
innervation and, potentially, via targeting M3R signalling on beta cells have thus far not 
been described. Furthermore, in addition to acetylcholine, parasympathetic neuronal endings 
in the pancreas release a multitude of other neurotransmitters (71). It remains unclear 
whether hypothalamic signals relayed by the vagus that modulate beta cell function act 
directly via beta cell muscarinic receptors or indirectly via cholinergic stimulation of an 
intermediary ganglion, from where secondary efferent neurotransmission is relayed to the 
beta cell.
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The sympathoadrenal and adrenergic innervation of islets modulates insulin secretion in 
rodents, while its role in humans remains unclear. Chemical sympathectomy results in 
decreased basal and glucose-stimulated insulin levels in mice but not in rats (85). 
Adrenalectomy also results in reduced basal insulin levels in mice, suggesting that not only 
sympathetic innervation but also circulating adrenal hormones modulate beta cell function 
(85). More recently, genetic mouse models with defined ablation of adrenergic signalling in 
islets was reported to result in disturbed islet architecture and functional maturation of beta 
cells (86).
Furthermore, galanin, which is abundantly expressed in neuroendocrine in the intestinal tract 
and also in neuronal endings surrounding the islets of Langerhans, suppresses glucose-
stimulated insulin (26, 87) (see above).
Central unresolved questions
From this overview it is clear that many important aspects of how beta cell function is 
regulated remain unanswered. There are likely to be additional signals involved in regulating 
beta cell function that will be revealed. With these anticipated advances the following 
central and enduring questions will need to be revisited as this research field moves forward:
1. How translatable are observations on inter-organ regulation of beta cell function 
made in experimental mouse models to the situation in human (patho-)physiology?
2. What is the hierarchy among the different stimuli that modulate beta cell insulin 
secretion?
3. Can impaired beta cell function in type 2 diabetes mellitus be sub-classified into 
groups of beta cell autonomous and non-beta cell autonomous downregulation of 
glucose-dependent insulin release?
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Abbreviations
DLK-1 Delta-like 1
DPP-IV Dipeptidyl peptidase IV
ERK Extracellular signal-regulated kinase
GIP Glucose-dependent insulinotropic polypeptide
GIPR Glucose-dependent insulinotropic polypeptide receptor
GLP-1 Glucagon-like peptide 1
GOAT Ghrelin O-acyltransferase
GSIS Glucose-stimulated insulin secretion
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M3R M3 acetylcholine receptor
NMUR Neuromedin U receptor
TCF1 T cell-specific transcription factor-1
PYY Peptide YY
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Fig. 1. 
Inter-organ communication pathways influencing beta cell function. The figure depicts the 
current understanding of principal inter-tissue signalling pathways that modulate GSIS from 
pancreatic beta cells. Signals modulate beta cell function in both positive (arrows) and 
negative (double bars) directions. The individual pathways are described in the main text. α, 
alpha cell; β, beta cell; Glu-OCN, Glu-OCN, undercarboxlated osteocalcin
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